NCT07041281 · Massachusetts General Hospital
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
(IMPACT-HT)
What this study is about
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy.
View original scientific description
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Females aged ≥18 years
- Antepartum-onset HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension
- BMI ≥25 kg/m2 prior to pregnancy or in the first trimester
- Requirement for antihypertensive medication on postpartum discharge
- Ability to provide informed consent
Exclusion criteria
- LV ejection fraction \<50% or history of clinical heart failure with reduced or preserved ejection fraction
- Hypertrophic or other genetic cardiomyopathy
- Hyperkalemia: potassium \>5.3 mEq/L
- BMI at screening ≥50 kg/m2 (to ensure accurate BP measurement and adequate echocardiographic images for analysis)
- Pre-pregnancy diabetes
- Estimated glomerular filtration rate (eGFR) \<60mL/min/1.73 m2
- Primary aldosteronism
- Intention to become pregnant within 9 months
- Active substance abuse
- Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months
- Participation in another interventional clini
Where
- Boston, Massachusetts
- Pittsburgh, Pennsylvania
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 3, 2026 · Source of record for eligibility and locations